Rethink Cell Therapy With LNPs

Lipid nanoparticles (LNPs) represent a groundbreaking advancement in non-viral delivery systems, offering a safe and efficient method for transporting nucleic acids—such as mRNA and gene editing tools—into cells. These tiny, protective carriers have already demonstrated their transformative potential in high-impact applications, most notably in the development of COVID-19 mRNA vaccines and CRISPR-based gene editing. Now, the versatility of LNPs is being harnessed for engineered cell therapy workflows that include CAR T-cell therapies and hematopoietic stem cell (HSC) modifications. This evolution opens exciting possibilities for next-generation cell therapies that are more precise, scalable, and consistent.

As the field of cell and gene therapy continues to evolve, discover how these advanced delivery systems can help you unlock new therapeutic frontiers.